Back

The connoisseurs

Regular users

Current states

Has the expertise to understand the differences between toxins, but Continue to use Botox alongside Dysport® as I like to have multiple ‘tools’ at my disposal

Desired states

Believe IPSEN provide exceptional partnership to injectors and as a result of the learning opportunities provided, Motivated to put Dysport® to the test across a broader range of patient types

Communication objectives

  1. A.Reinforce the added value of Dysport® with strong data which makes it the toxin of choice (especially in complex cases)

  2. Generate excitement to work with IPSEN and share their own perspective on Dysport® with other HCPs

target

Messaging should be science-led, offering technical details and statements that challenge the HCP.

Communication objective associated: Reinforce the added value of Dysport® with strong data which makes it the toxin of choice (especially in complex cases)

  1. Achieve meaningful, patient-centered goals for a broader range of patients: ULIS III and AboLiSh show Dysport® delivers meaningful, patient-centered outcomes across a wide spectrum of adult spasticity cases
  2. Clinical data support tailored injection strategies cycle-by-cycle optimization leads to sustained functional gains
  3. Advanced goal attainment is achievable using individualized dosing and muscle selection, as documented in real-world cohorts.

Key supportive study :

  • Upper limb ULIS III : Turner-Stokes L et al., J Rehabil Med. 2021;53(1):jrm00133
  • Lower limb AboLish: Esquenazi A, et al. Arch Phys Med Rehabil. 2024

Key material

  • CLM presentation
  • AboLiSh infographic
  • ULIS III infographic

Digital material for follow up

  • VAE AboLish / ULIS III (to come)
  • VAE Goal setting (to come)
  • Goal setting podcast Jacinto 
  • Goal setting video Jacinto

Communication objective associated: Reinforce the added value of Dysport® with strong data which makes it the toxin of choice (especially in complex cases)

  1. The Dysport® duration of effect may be positively correlated with dose, which in turn correlates with a greater amount of active neurotoxin administered9
  2. ULIS III real-world data demonstrate significantly longer intervals between Dysport® injections compared to other BoNT-As in upper limb spasticity.
  3. AboLiSh study shows a mean reinjection interval of 18.3 ± 6.1 weeks in ambulatory lower limb spasticity, with cumulative goal gains documented across cycles.

Key supportive study :

  • High amount of neurotoxin: . Field M, et al. Toxins. 2018;10:535
  • ULIS III : Turner-Stokes L et al., J Rehabil Med. 2021;53(1):jrm00133
  • AboLiSh : Esquenazi A et al., Arch Phys Med Rehabil. 2024.

Key material

  • CLM presentation

Digital material for follow up

  • Esquenazi webinar 
  • Jacinto reflection 
  • VAE on duration of response (to come)

Communication objective associated: Reinforce the added value of Dysport® with strong data which makes it the toxin of choice (especially in complex cases)

  1. Dysport® contains the highest active neurotoxin content per licensed dose among BoNT-As, enabling tailored treatment strategies for complex spasticity cases
  2. Individualized Dysport® regimens supported by evidence-based dosing and advanced injection techniques allow clinicians to tailor treatment to each patient’s needs.
  3. Dysport® exhibits a dose-response relationship, with higher doses correlating to extended duration of effect and greater improvements in muscle tone, as demonstrated in phase III trials
  4. Recommended doses for upper/lover limb spasticity

Key supportive study :

  • Upper limb: Gracies J, et al. Muscle Nerve. 2018;57(2):245-254
  • Lower limb: Gracies J, et al. Neurology. 2017;89(22):2245-2253
  • Amount of Neurotoxins: Field M, et al. Toxins. 2018;10:535

Key material

  • CLM presentation

Digital material for follow up

  • Ixcellence website – Echo modules

Communication objective associated: Generate excitement to work with IPSEN and share their own perspective on Dysport® with other HCPs

  1. You have the power to deliver lasting control between treatment cycles and help prevent the early
    return of debilitating symptoms
  2. IXCELLENCE: the IPSEN Neuroscience HCP Training Program on the use of Dysport and spasticity management
  3. IXCELLENCE website to support you in your training journey with Dysport
  4. Dosing app to support you selecting the right dose at the right time

Key material

  • CLM presentation
  • Ixcellence website

Digital material for follow up

  • Invitation to (inter)national training